A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
NCT02874664
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Small Cell Lung Carcinoma
Interventions
DRUG:
Rovalpituzumab Tesirine
Sponsor
Stemcentrx